Document Detail

Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
MedLine Citation:
PMID:  22520494     Owner:  NLM     Status:  Publisher    
PURPOSE: The aim of the study was to analyze the response to the vasopressin-receptor antagonist conivaptan in a large cohort of brain-injured patients with acute hyponatremia. MATERIALS AND METHODS: The natremic response (rise in serum sodium) to an initial bolus of conivaptan was retrospectively evaluated in 124 patients over a 3-year period in our neurosciences intensive care unit. Variables associated with this response were identified using linear regression. RESULTS: Median pretreatment sodium was 132 mEq/L, and duration of hyponatremia before dose was 1 day. Median natremic response was +4 mEq/L (interquartile range, 2-7 mEq/L), measured a median of 9 hours (interquartile range, 6-12 hours) after conivaptan administration. This was associated with significant urine output (median, 2.6 L over 12 hours), with degree of aquaresis associated with natremic response (regression coefficient, B = 1.8 change in sodium per liter; 95% confidence interval, 1.3-2.4; P < .001). Seventy-four patients (60%) responded with a rise of at least 4 mEq/L. Response was predicted by higher baseline urine output (B = 0.018 per mL; 0.004-0.032; P = .01) and lack of oral fluid intake (B = 2.06; 0.44-3.68; P = .01) but not tonicity of intravenous fluids or creatinine clearance. CONCLUSIONS: Conivaptan given as a bolus can effectively treat acute hyponatremia in brain-injured patients.
Theresa Human; Adaeze Onuoha; Michael Diringer; Rajat Dhar
Related Documents :
3786754 - Differential diagnosis of bronchiolitis obliterans with organizing pneumonia and usual ...
8281354 - Pulmonary function abnormalities in patients with primary sjögren's syndrome.
15945534 - Usual interstitial pneumonia complicating dyskeratosis congenita.
15996064 - Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a m...
3940364 - Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis.
19903174 - Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-18
Journal Detail:
Title:  Journal of critical care     Volume:  -     ISSN:  1557-8615     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8610642     Medline TA:  J Crit Care     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Department of Clinical Pharmacy, Neurology/Neurosurgery Intensive Care Unit, Barnes-Jewish Hospital, Saint Louis, MO, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of pattern of admission on outcomes after aneurysmal subarachnoid hemorrhage.
Next Document:  Changes in heart rate, mean arterial pressure, and oxygen saturation after open and closed endotrach...